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CORRESPONDENCE 
JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a 
series of 349 patients  
TO THE EDITOR 
Several groups have recently reported the presence of a unique gain-of-function JAK2 point 
mutation (V617F) in the majority of cases of classic cMPD as well as in a minority of atypical 
MPDs and in occasional cases of AML. To date, this mutation has not been reported in normal 
controls, lymphoid disorders or in patients with secondary erythrocytosis (1-10). 
In this study, we have analyzed bone marrow or peripheral blood samples from 349 patients  
(PV, n = 84; ET, n = 243; IMF, n = 22) referred to our diagnostic service for cytogenetic 
analysis and/or exclusion of the BCR-ABL fusion from several hospitals in the north of Spain 
between 1996 and 2005. Our study group thus includes the largest series of ET cases reported to 
date for JAK2 analysis. DNA was extracted and tested for V617F by a sensitive amplification 
refractory mutation system (ARMS) as described previously (6). Results were obtained from all 
samples and V617F was detected in 80%, 62% and 68% of cases of PV, ET and IMF, 
respectively (Table 1). These frequencies are comparable to other studies for PV and IMF, but 
somewhat higher than expected for ET, for which 23-57% of cases have been reported as 
V617F positive. Part of the reason for this is probably attributable to technical differences in the 
sensitivity of the V617F detection. Most other studies used sequencing, which can 
underestimate the proportion of positive patients (2,6), whereas allele-specific PCR assay is 
capable of detecting a mutation present in 1-2% of cells (6).  
Of the 17 V617F negative PV cases our series, only two were female (P=0.044, contingency 
χ2=4.058). This supports the previous observation of a significant male excess in mutation 
negative PV cases (6). In addition a relative risk ratio estimate (RR=1.26; confidence interval 
95%=1.04-1.52) of our data indicated that V617F is 26% more frequent in PV females 
compared to PV males (Table 1). 
PV and IMF are both considered to be clonal diseases, but for ET only approximately half of 
cases are clonal, the remainder being polyclonal and therefore presumably reactive. It has been 
suggested (6) that the great majority of clonal ET cases must be V617F positive, but it remains 
to be determined if any V617F ET cases are also clonal. To address this question, we compared 
karyotypes between mutation negative and mutation positive cases. Of the 191 ET cases for 
whom cytogenetic analysis had been successfully performed, clonal cytogenetic abnormalities 
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were observed in 11 of the 118 (9%) V617F positive and 5 of the 73 (7%) V617F negative 
patients (Table 2). Although the frequency of chromosome abnormalities is lower in V617F 
negative ET cases, these data show that at least some of these cases are indeed clonal. 
Karyotypes were also available for 79 of the 85 PV patients (V617F positive, n = 62; V617F 
negative, n = 17) and 19 of the 22 IMF cases (V617F positive, n = 12; V617F negative, n = 7) 
(Table 2). For PV, 11 V617F positive patients had cytogenetic abnormalities, of which three 
showed del(20q), four showed +9 and four had -Y or +8. A single V617F negative PV patient 
was karyotypically abnormal with del(20q). For IMF patients, all of V617F positive cases had a 
normal karyotype whereas two of the negative V617F patients showed aberrations (Table 2). 
Thus, on the basis of cytogenetics, it is clear that some V617F negative cMPD cases have a 
clonal disease, suggesting the existence of uncharacterised mutation/s that may or may not lie in 
the same signal transduction pathway. Currently, it is not clear if JAK2 V617F is the initiating, 
disease causing mutation or an important secondary event. However our finding of known 
recurrent cytogenetic abnormalities in both V617F positive and negative cases supports the 
notion that the development of cMPDs is a multistep pathogenetic process. 
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Table 1. JAK2 V617F mutation frequencies (separated by gender) 
Sex V617F JAK2 positive V617F JAK2 negative 
PV patients (n = 84)   
Male (n = 57) 42 (74%) 15 (26%) 
Female (n = 27) 25 (93%) 2 (7 %) 
ET patients (n = 243)   
Male (n = 130) 85 (65%) 45 (35%) 
Female (n = 113) 65 (58%) 48 (42%) 
IMF patients (n = 22)   
Male (n = 15) 11 (73%) 4 (27%) 
Female (n = 7) 4 (57%) 3 (43%) 
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Table 2. Karyotypic abnormalities observed. The number of metaphases are between brackets. 
 V617F JAK2 status Karyotype 
PV patients (n = 12/79) 
PV1 Negative 46,XY/46,XY,del(20)(q13) 
PV2 Positive 46,XY[28]/47,XY,+9[2] 
PV3 Positive 46,XY[4]/45,X,-Y[26] 
PV4 Positive 46,XY[9]/46,XY,del(20)(q13)[21] 
PV5 Positive 46,XY[3]/47,XY,+9[27] 
PV6 Positive 46,XY[19]/45,X,-Y[11] 
PV7 Positive 46,XY[28]/47,XY,+9[2] 
PV8 Positive 46,XY[2]/47,XY,+9[36] 
PV9 Positive 46,XY[13]/46,XY,del(20)(q12)[17] 
PV10 Positive 47,XY,+8[30] 
PV11 Positive 45,X,-Y[30] 
PV12 Positive 46,XY,del(20)(q12)[30] 
ET patients (n = 16/191) 
ET1 Positive 46,XX[14]/45,XX,-5,del(9)(q22?),1dmin[16] 
ET 2 Positive 46,XX,del(5)(q14q22)[31] 
ET3 Negative 46,XY[4]/45,XY,-7[31] 
ET4 Positive 46,XY[28]/47,XY,+8[2] 
ET5 Positive 46,XX[17]/46,XX,+der(15)t(1;15)(q12;p13),-15[13] 
ET6 Positive 46,XX,inv(9)(p12;q13)[30] 
ET7 Positive 46,XX,del(20)(q3)[32] 
ET8 Negative 46,X,-Y[30] 
ET9 Positive 46,XX[21]/45,XX,-21[9] 
ET10 Positive 46,XY[12]/46,XY,del(9)(q12q22)[23] 
ET11 Positive 46,XY[24]/47,XY,+9[6] 
ET12 Negative 46,X[29]/46,XY,del(5)(q23q33)[3] 
ET13 Negative 46,XY[20]/47,XY,+8[15] 
ET14 Positive 46,XY[24]/47,XY,+9[6] 
ET15 Negative 46,XX [29]/47,XX,+12 [1] 
ET16 Positive 47,XX,+9[30] 
IMF patients (n = 2/22) 
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IMF1 Negative 46,XY[7]/46,XY,del(1)(p33)[23] 
IMF2 Negative 46,XX,t(12;12)(p11;q13)[30] 
 
 
 
